Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Gemcitabine or Gemcitabine combination

Klinikum Großhadern, University of Munich / Medical Director: Prof. Dr. med. Burkhard Götze0 个研究点目标入组 75 人开始时间: 2006年6月21日最近更新: 2012年11月19日

试验速览

暂无简介。

•Histologically confirmed diagnosis of a locally advanced inoperable or intraabdominal (including hepatic) metastatic pancreatic adenocarcinoma with progression under preceding first-line-chemotherapy with Gemcitabine or Gemcitabine combination, or with progress during or after adjuvant chemotherapy with Gemcitabine or Gemcitabine combination
•Karnofsky Performance status >= 70
•signed informed consent
•life expectance of at least 12 weeks
•sufficient organic function
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Preceding firstline chemotherapy with chemotherapeutic agents other than gemcitabine alone or in combination
•second malignancy
•allergy to any of the drugs used
•active infection
•polyneuropathy
•hyperthermia treatment technically not conductable

发起方

Klinikum Großhadern, University of Munich / Medical Director: Prof. Dr. med. Burkhard Götze